Probe Melting Technology for Rapid Detection of Drug Resistant Tuberculosis (PMTforDR-TB)

May 16, 2016 updated by: Yanming Li, Beijing Hospital

Multi Center Clinical Research and Evaluation of Melting Technology for Rapid Detection of Drug Resistant Tuberculosis

Background:

Drug resistant tuberculosis is a serious public health problem that threatens the health of human life and the development of society and economy. At present, the diagnosis of drug-resistant tuberculosis mainly depends on traditional drug susceptibility test. But it is limited in Mycobacterium tuberculosis slow growth speed, traditional solid drug sensitivity test usually need to 3 months to results, delay the development of drug resistance in patients with effective treatment. Probe melting curves resistance detection technology is the recent emergence of a new molecular biology and drug resistant tuberculosis detection technology, probe melting curves with different fluorescent labeled probe coverage detection specific to M.tuberculosis drug resistance determining region, through changes in the melting point of the probe hybridization, acquire mutation information of detection region, shorten detection time and detect nonuniform resistance.

In this study, by selecting a nationally representative in different levels of hospitals jointly launched multi center, large sample clinical assessment, completed the comprehensive evaluation of sensitivity, specificity and health economics of drug resistant pulmonary tuberculosis, especially resistance to multidrug and extensively drug-resistant TB patients detection,in order to evaluate the rapid, accurate and economic and appropriate technology of drug resistance pulmonary tuberculosis detection.

In order to accomplish the overall goal of the project, in the framework of the overall design, according to the principles of the core tasks are divided into four sub topics, namely:

Sub topic 1 of the core mission is included in 3100 cases of smear positive pulmonary TB suspicious symptoms, from which selected more than 1000 cases of drug-resistant pulmonary tuberculosis patients, using MGIT liquid culture and drug sensitivity test as the gold standard,evaluate the sensitivity and specificity of probe melting curves in detction of resistance of four kinds of anti tuberculosis drug to Mycobacterium tuberculosis; Sub topic 2 core task is including at least 500 cases of culture positive pulmonary tuberculosis patients and treatment follow-up, using MGIT liquid culture and drug sensitivity test as the gold standard, evaluate the application value of probe melting curves for monitoring spectrum changes of drug resistance of Mycobacterium tuberculosis during pulmonary tuberculosis treatment.

The core mission of sub topic 3 is to project implementation of hospital as the research site,acquire the cost-effect evaluation and analysis by comparing probe melting technology with Mycobacterium tuberculosis MGIT liquid culture, and drug sensitivity test with xpert MTB/RIF technology.

Study Overview

Status

Unknown

Conditions

Detailed Description

Sub topic 1:Probe melting curve method for the analysis of drug resistance detection technology for detection of Mycobacterium tuberculosis resistance performance analysis.

Research methods: multi center clinical study. Research object: sputum acid fast staining microscopy positive of pulmonary tuberculosis with suspicious symptoms.

Technical principle and operation method: see attachment.

Entry criteria:

1) during the study of all smear positive pulmonary tuberculosis with suspicious symptoms; 2) can provide 3-4ml sputum samples three times in 2 days; 3) informed consent. Exclusion criteria: the quality of sputum specimen is not qualified (sputum sample is less than 3ml or saliva sputum).

  1. sample estimate Method and formula: according to the national tuberculosis drug resistance in the baseline survey results, isoniazid, rifampicin, fluoroquinolones and streptomycin anti tuberculosis drugs, fluoroquinolones resistance rate is low; using fluoroquinolones detection estimation sample content, can meet the needs of other anti tuberculosis drug resistance rate analysis.
  2. observation index: (1) basic information: demographic data, underlying diseases, the diagnosis and treatment of tuberculosis, epidemiological characteristics.

(2) the clinical symptoms and signs: fever, night sweats, cough, sputum and sputum, weight loss, hemoptysis or sputum with blood, chest pain, dyspnea, fatigue, height, weight, pulmonary rales.

(3) chest imaging (chest X-ray or CT scan): the specific description of the lesion distribution and morphological characteristics and scoring.

(4) laboratory examination: erythrocyte sedimentation rate (ESR), blood routine test, blood biochemistry (AST, ALT, TP, ALB, BUN, Cr and Glu), C-reactive protein (CRP).

(5) microbiological examination of sputum, sputum acid fast staining microscopy, MGIT liquid culture and drug sensitivity detection, xpert MTB/RIF, probe melting curves technology.

95% confidence intervals, using statistical methods by chi square test and Kappa test.

sub topic 2:the follow up of diagnosis and treatment in application of Probe melting curve method of resistance detection in patients with pulmonary tuberculosis.

Research methods: multi center clinical study. Study subjects and sample size: MGIT liquid culture positive pulmonary tuberculosis patients in sub topic 1, to be included in at least 500 cases.

Entry criteria and exclusion criteria: the same as the research sub topic 1.

1 observation index:

  1. with the clinical symptom and physical sign of diagnostic node changes: fever, night sweats, cough, sputum and sputum, weight loss, hemoptysis or sputum with blood, chest pain, dyspnea, fatigue, height, weight, pulmonary rales.
  2. the changes of chest imaging in the follow up nodes: a detailed description of the image.
  3. with the clinical examination of diagnostic node: erythrocyte sedimentation rate (ESR), blood routine test, blood biochemistry (AST, ALT, TP, ALB, BUN, Cr and Glu), C-reactive protein, and so on.
  4. with diagnosis node sputum microbiology examination: sputum acid fast staining microscopy, MGIT liquid drug sensitive culture, Xpert-MTB/RIF and probe melting curves.

  5. classification of outcomes:

    1. effective: to complete the prescribed course of treatment, sputum culture negative; chest X-ray absorption improvement;
    2. failure: treatment for 6/8 months with smear / culture examination positive and / or radiographic improvement;
    3. non tuberculosis deaths: death due to causes other than tuberculosis;
    4. tuberculosis death: death due to disease progression or complications; (E) shedding: interruption of treatment and follow-up can not be achieved;

    (f) diagnostic change: diagnosis of pulmonary tuberculosis in the treatment process.

  6. the change of drug resistance spectrum (a) drug resistance spectrum change: the change of drug resistance of Mycobacterium tuberculosis in the course of follow-up; (b) not uniform resistance: refers to the of the results of the original probe melting curve resistance detection technology analysis, it is found that the probe melting curve peak spectrum chart presents the characteristics of two kinds of different genotype.

2.quality control and acceptance: the same research sub topic 1. 3 data statistics and analysis: Probe melting curves,the molecular diagnostic technique in patients with pulmonary tuberculosis treatment with statistical methods is the application of diagnosis in the calculated two-sided 95% confidence interval, chi square test and kappa test.

sub topic 3:Probe melting curve technology for the cost-effect analysis in detection of drug-resistant Mycobacterium tuberculosis.

Methods: using the cost analysis method and the questionnaire. Research object: research project implementation hospital laboratory.

Data collection, statistics and analysis:

1 cost analysis

  1. each of the implementation of the following basic data collection and data entry software.

    1. the basic costs: were collected for the implementation of the hospital basic input costs, including laboratory housing area, housing area of the office area, laboratory construction and renovation costs, considering the useful life of housing, the conversion of housing cost per unit time.
    2. laboratory equipment costs: all experimental equipment of the cost in purchasing the new price to calculate and the cost should include all procurement costs associated with, such as transportation, installation; annual collection of major equipment maintenance / repair costs, according to the useful life of the instrument, converted instrument unit time cost.
    3. laboratory management costs: laboratory water, electricity, garbage disposal fees, heating costs, etc.;
    4. personnel costs: laboratory staff wages, including all bonuses and allowances paid to employees; (E) cost of supplies: laboratory, including gloves, laboratory clothing, hats, conventional reagents, such as the unit price;

    (f) the above collection cost input software, as a basis for the implementation of the basic data of the hospital;

  2. selection of opportunity cost method, were three projects in the implementation of hospital laboratory independently collected nine laboratory personnel process time, the use of instruments, reagents, consumables and the number of consumption, accurately to the recorded in the tables of statistics in; every collection cost shall cover high, medium and low different sample size, average value of 3 times the amount of sample; will collect the data and time consuming product data entry forms, different batches of cost calculation, will each region three times the cost of taking the average value is real-time fluorescent nucleic acid isothermal amplification detection technique for each detection unit.
  3. to analyze the prevalence rate of tuberculosis in different projects, and to calculate the cost of tuberculosis patients in different regions.

2 acceptance survey: the design of the questionnaire, the survey of 3 projects in the implementation of the hospital not less than 10 laboratory technicians. The questionnaire covers the convenience of other methods, the needs of the laboratory, the application prospects and other aspects of the content.

Study Type

Observational

Enrollment (Anticipated)

3100

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

  • Name: Yanming Li, Principal Investigator
  • Phone Number: 13701097436
  • Email: lymyl@263.net

Study Contact Backup

  • Name: Shuyi Si, subordinate
  • Phone Number: 13051991568
  • Email: shy_si@163.com

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

16 years and older (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Sampling Method

Non-Probability Sample

Study Population

the population of suspected symptoms of tuberculosis with sputum smear microscopy positive

Description

Inclusion Criteria:

  1. During the study of all smear positive pulmonary tuberculosis with suspicious symptoms
  2. Can provide 3-4ml sputum samples three times in 2 days
  3. Informed consent

Exclusion Criteria:

  • The quality of the sputum sample is not qualified (the sputum sample is less than 3ml or saliva sputum)

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Observational Models: Case-Only
  • Time Perspectives: Prospective

Cohorts and Interventions

Group / Cohort
MGIT liquid culture+drug sensitivity test
MGIT: The bactec MGIT 960 system is non-radiometric. It uses MGIT media and patented sensors, making efficient use of advanced fluorometric technology, which permits highly accurate detection of O2 consumption without sharps. Automated quality control is performed continuously to ensure precise and reliable operation. Results are provided as positive/negative and numerical growth units.
Xpert-MTB/RIF
xpert-MTB/RIF: The Xpert MTB/RIF assay is a nucleic acid amplification (NAA) test that uses a disposable cartridge with the GeneXpert Instrument System. A sputum sample is collected from the patient with suspected TB. The sputum is mixed with the reagent that is provided with the assay, and a cartridge containing this mixture is placed in the GeneXpert machine. All processing from this point on is fully automated.The test simultaneously detects Mycobacterium tuberculosis complex (MTBC) and resistance to rifampin (RIF) in less than 2 hours.
probe melting curve detection
Probe-based fluorescence melting curve analysis (FMCA) is a powerful tool for mutation detection based on melting temperature generated by thermal denaturation of the probe-target hybrid, which performed for Mycobacterium tuberculosis's drug resistant monitor. The method was explored two dual-labeled, self-quenched probes, TaqMan and shared-stem molecular beacons, in their ability to conduct FMCA. Both probes could be directly used for FMCA and readily integrated with closed-tube amplicon hybridization under asymmetric PCR conditions. Improved flexibility of FMCA by using these probes was illustrated in three representative applications of FMCA: mutation scanning, mutation identification and mutation genotyping, all of which achieved improved color-multiplexing with easy probe design and versatile probe combination and all were validated with a large number of real clinical samples.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
the sensitivity and specificity of probe melting curves technology
Time Frame: up to 3.5 years
assess the sensitivity and specificity of probe melting curves for four kinds of anti tuberculosis drug resistance to Mycobacterium tuberculosis.
up to 3.5 years
Comparison of diagnostic efficacy
Time Frame: from January,2015 to December,2018
Using Xpert-MTB/RIF as control technology, the diagnostic efficacy of two kinds of drug resistance detection technology was compared.
from January,2015 to December,2018
Evaluation of the application value of probe melting curve technology
Time Frame: up to 3.5 years
For the first time in China to carry out drug-resistant TB rapid detection technology appllied in the follow-up, improve the resistance detection technology to monitor the change of TB drug resistance spectrum in the treatment of pulmonary tuberculosis.Selecting patients with MGIT liquid culture positive pulmonary tuberculosis(selected from sub topic1) were included in the study，at least 500 patients were included in the study.Observe the outcomes and the change of drug resistance spectrum.drug-resistant TB rapid detection technology applied in the follow-up of patients with pulmonary TB by monitoring TB drug resistance spectrum change,provides the basis for the resistant phenotype and genotype identification and diagnosis of nonuniform resistance.Data statistics and analysis:95% confidence intervals, chi square test and Kappa test were calculated respectively.
up to 3.5 years
analyze the cost-effect assessment of probe melting curve technology and other two kinds of detection methods
Time Frame: up to 3.5 years

Complete the cost-effectiveness assessment analysis of the probe melting curve technology compared with Mycobacterium tuberculosis MGIT liquid culture and drug sensitivity test,and xpert MTB / RIF technology.

Methods:Using cost analysis and acceptability questionnaire.Each of the implementation of the hospital, collecting the basic data and input the costs into the software,using opportunity cost method.
up to 3.5 years

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Beijing Hospital

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

General Publications

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start

May 1, 2016

Primary Completion (Anticipated)

December 1, 2018

Study Completion (Anticipated)

June 1, 2019

Study Registration Dates

First Submitted

May 10, 2016

First Submitted That Met QC Criteria

May 16, 2016

First Posted (Estimate)

May 18, 2016

Study Record Updates

Last Update Posted (Estimate)

May 18, 2016

Last Update Submitted That Met QC Criteria

May 16, 2016

Last Verified

May 1, 2016

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

  • BeijingH

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

Yes

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Tuberculosis, Pulmonary

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Estonia

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

3
Subscribe